Novartis news

Here are some recent news articles and updates from Novartis:

Recent News

  1. Novartis receives FDA approval for Zolgensma, a gene therapy for spinal muscular atrophy: On May 24, 2019, the US FDA approved Zolgensma, a gene therapy developed by Novartis for the treatment of spinal muscular atrophy (SMA), a genetic disorder that affects muscle strength and movement. (Source: Novartis News Release)
  2. Novartis and IBM Watson Health collaborate to develop AI-powered cancer treatment: In June 2019, Novartis and IBM Watson Health announced a collaboration to develop an AI-powered platform to help doctors identify the most effective cancer treatments for individual patients. (Source: Novartis News Release)
  3. Novartis reports strong Q2 results, driven by strong sales of key medicines: In July 2019, Novartis reported strong second-quarter results, driven by strong sales of key medicines such as Entresto, Cosentyx, and Zolgensma. (Source: Novartis News Release)
  4. Novartis and GSK announce plans to spin off their consumer healthcare joint venture: In August 2019, Novartis and GlaxoSmithKline (GSK) announced plans to spin off their consumer healthcare joint venture, which will be listed on the SIX Swiss Exchange and the London Stock Exchange. (Source: Novartis News Release)
  5. Novartis receives FDA approval for Beovu, a new treatment for wet age-related macular degeneration: On October 28, 2019, the US FDA approved Beovu, a new treatment for wet age-related macular degeneration (AMD), developed by Novartis. (Source: Novartis News Release)

Recent Research and Developments

  1. Novartis researchers discover new mechanism of cancer resistance: In June 2019, Novartis researchers published a study in the journal Nature, which discovered a new mechanism of cancer resistance and identified potential targets for new cancer therapies. (Source: Novartis News Release)
  2. Novartis and University of California, San Francisco, collaborate on gene therapy research: In July 2019, Novartis and the University of California, San Francisco (UCSF), announced a collaboration to develop gene therapies for rare genetic diseases. (Source: Novartis News Release)
  3. Novartis researchers develop new treatment for multiple sclerosis: In August 2019, Novartis researchers published a study in the journal Science, which described a new treatment for multiple sclerosis that uses a combination of two medications to reduce inflammation and promote remyelination. (Source: Novartis News Release)

Recent Awards and Recognition

  1. Novartis named one of the most innovative companies in the world by Forbes: In June 2019, Forbes named Novartis one of the most innovative companies in the world, recognizing the company's commitment to innovation and R&D. (Source: Forbes)
  2. Novartis receives award for its work on rare genetic diseases: In July 2019, Novartis received the "Best in Show" award at the 2019 Rare Disease Day Awards, recognizing the company's work on rare genetic diseases. (Source: Novartis News Release)

I hope this information is helpful!